Tools   Select Another Resource Report Type

http://www.uchicagoddrcc.org/research-cores/administrative-core

Core that has oversight of the other four cores of University of Chicago's Digestive Disease Research Core Center and determines the center's overall direction.

Proper citation: University of Chicago Digestive Diseases Research Core Center Administrative Core (RRID:SCR_015602) Copy   

•   Source: SciCrunch Registry

http://www.uchicagoddrcc.org/research-cores/host-microbe-core

Core that consists of two components: The Enteric Microbiology and The Gnotobiotic Mouse components. The Enteric Microbiology component offers novel screening and advanced technologies for compositional and functional profiling of the resident microbial communities in the gastrointestinal tract. The Gnotobiotic Mouse component enables investigators to study the effects and causal role of specific microorganisms or profiles in vivo.

Proper citation: University of Chicago Digestive Diseases Research Core Center Host-Microbe Core (RRID:SCR_015603) Copy   

•   Source: SciCrunch Registry

http://www.mayo.edu/research/centers-programs/obrien-urology-research-center/cores/imaging

Core that provides renal stone imaging and analysis techniques, including dual energy CT data acquisition and analyses, dual energy material decomposition analysis, high-resolution image reconstruction and analysis, and coordination of micro-CT scanning and data analysis.

Proper citation: Mayo Clinic O'Brien Urology Center Imaging Core (RRID:SCR_015454) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org/drc-cores/molecular-phenotyping-and-genotyping-core

Core facility that supports the study of molecular mechanisms of disease by providing equipment, expertise, and services in molecular phenotyping, including nucleic acid sequence analyses, gene expression, and other "omics" analyses, which would be too specialized or costly for individual laboratories to perform independently. Formerly known as the Advanced Genomics and Genetics Core, the Molecular Phenotyping Core is newly-named in recognition of the expansion of its analytical capacities to reflect not only genetic and genomic analyses but also metabolic phenotyping.

Proper citation: Joslin Diabetes Center Molecular Phenotyping and Genotyping Core (RRID:SCR_015733) Copy   

•   Source: SciCrunch Registry

http://www.mayo.edu/research/centers-programs/obrien-urology-research-center/cores/urine-phenotyping

Core that aims to increase understanding of the factors that modulate the interface of urinary proteins and crystals, and hence their subsequent interaction with other crystals or cells. Its services include quantification of urinary components of the supersaturation profile, quantification of urinary inhibitor activity, quantification of known urinary macromolecular inhibitors, and application of differential proteomics to urine samples of stone forming and control populations.

Proper citation: Mayo Clinic O'Brien Urology Center Urine Phenotyping Core (RRID:SCR_015455) Copy   

•   Source: SciCrunch Registry

http://www.med.umich.edu/mgpc/cores/mbc.htm

Core whose services include the following programs: Transgenic Rodent Program, Genome Editing Program, Viral Vector Program, and Integrated Genomics Program.

Proper citation: University of Michigan Center for Gastrointestinal Research Molecular Biology Core (RRID:SCR_015610) Copy   

•   Source: SciCrunch Registry

http://depts.washington.edu/uwnorc/core-facilities/adipose-tissue-and-obesity-core/

Core that provides affiliated investigators with assistance for in vivo and in vitro studies in both subcutaneous and visceral human adipose tissue. Body and liver fat measurement by DXA and MRI are also provided, as is support for translational studies that assist investigators in the design conduct of clinical obesity research.

Proper citation: University of Washington Nutrition and Obesity Research Center Adipose Tissue and Obesity Core (RRID:SCR_015481) Copy   

•   Source: SciCrunch Registry

https://www.atypicaldiabetesnetwork.org/

Portal dedicated to characterizing, discovering and defining rare and atypical forms of diabetes. Network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Team of academic institutions and scientists collaborates with physicians and healthcare groups to identify those with atypical diabetes and learn more about their health.

Proper citation: Rare and Atypical Diabetes Network (RRID:SCR_024732) Copy   

•   Source: SciCrunch Registry

https://www.researchallofus.org

Portal stores health data from participants from across the United States. Provides interactive Data Browser where anyone can learn about the type and quantity of data that All of Us collects. Users can explore aggregate data including genomic variants, survey responses, physical measurements, electronic health record information, and wearables data.

Proper citation: All of Us (RRID:SCR_027032) Copy   

•   Source: SciCrunch Registry

http://rarediseasesnetwork.epi.usf.edu/porphyrias/

A consortium which includes five of the leading porphyria centers in the United States that provide expertise and experience in the diagnosis and treatment of patients with porphyria. The staff in each Center includes porphyria physicians, researchers, research coordinators, and technical/laboratory staff. Together with the American Porphyria Foundation, the Porphyrias Consortium enables a large scale collaborative effort to develop strategies and methods for diagnosis, treatment, and prevention of illness and disability resulting from these rare disorders.

Proper citation: Porphyria Consortium (RRID:SCR_014379) Copy   

•   Source: SciCrunch Registry

http://www.ckdbiomarkersconsortium.org/

A consortium which aims to promote the discovery and validation of biomarkers to advance the field of CKD research. The NIDDK CKD Biomarkers Consortium brings together investigators whose expertise includes clinical nephrology, epidemiology, molecular biology, genomics, proteomics, metabolomics, systems biology, laboratory medicine, biostatistics, and laboratory test verification and qualification.

Proper citation: CKD Biomarkers Consortium (RRID:SCR_014381) Copy   

•   Source: SciCrunch Registry

https://t1dexchange.org/pages/

Provides access to resources T1D researchers need to conduct clinical studies. Data sets from their clinic registry is openly available, as are new study results. They also offer use of T1D Discovery Tool, which allows users to search different fields from registry data, and T1D Exchange Biobank, which offers specimen types such as serum, plasma, white blood cells, DNA, and RNA.

Proper citation: T1D Exchange (RRID:SCR_014532) Copy   

•   Source: SciCrunch Registry

http://www.gudmap.org/euregene/pages/about_us.htm

A European organization primarily concerned with the study of renal disorders. The organization is working towards discovering the genes responsible for renal development, renal disease and the related proteins and their actions. EuReGene consists of a consortium of scientists, clinicians, and SME partners that study functional genomics and their application in kidney research.

Proper citation: EuReGene (RRID:SCR_014516) Copy   

•   Source: SciCrunch Registry

http://scgap.systemsbiology.net/project_description.php

A research organization which aims to conduct a variety of stem cell research projects. These projects include: to CD phenotype the human prostate and bladder using a confocal microscopy, to CD the phenotype of the mouse prostate and bladder, to profile samples of basal and stromal cells using uncultured cells, to confirm cell-type specific expression of genes that were identified by array analysis, and to create a database with the resulting database.

Proper citation: Stem Cell Genome Anatomy Projects (RRID:SCR_014517) Copy   

•   Source: SciCrunch Registry

http://commonfund.nih.gov/

Supports cross-cutting, trans-NIH programs that require participation by at least two NIH Institutes or Centers (ICs) or would otherwise benefit from strategic planning and coordination. The requirements for the Common Fund encourage collaboration across the ICs while providing the NIH with flexibility to determine priorities for Common Fund support. To date, the Common Fund has been used to support a series of short term, exceptionally high impact, trans-NIH programs known collectively as the NIH Roadmap for Medical Research. The Common Fund is coordinated by the Office of Strategic Coordination, one of the six offices of the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) within the Office of the Director. The intent of NIH Common Fund programs is to provide a strategic and nimble approach to address key roadblocks in biomedical research that impede basic scientific discovery and its translation into improved human health. In addition, these programs capitalize on emerging opportunities to catalyze the rate of progress across multiple biomedical fields. Common Fund programs are expected to transform the way a broad spectrum of health research is conducted. Initiatives that comprise Common Fund programs are intended to be catalytic in nature by providing limited term investments in strategic areas to stimulate further research through IC-funded mechanisms.

Proper citation: NIH Common Fund (RRID:SCR_012790) Copy   

•   Source: SciCrunch Registry

http://cdmrp.army.mil/

Fund the best research to eradicate diseases and support the warfighter to benefit the American Public. They promote innovative research, recognizing untapped opportunities, creating partnerships, and guarding the public trust. Research Program topics include: * Amyotrophic Lateral Sclerosis * Autism * Bone Marrow Failure * Breast Cancer * Defense Medical Research and Development Program * Duchenne Muscular Dystrophy * Gulf War Illness * Lung Cancer * Multiple Sclerosis * Neurofibromatosis * Ovarian Cancer * Peer Reviewed Cancer * Peer Reviewed Medical * Peer Reviewed Orthopaedic * Prostate Cancer * Psychological Health / Traumatic Brain Injury * Spinal Cord Injury * Tuberous Sclerosis Complex

Proper citation: Congressionally Directed Medical Research Program (RRID:SCR_006456) Copy   

•   Source: SciCrunch Registry

http://kidney.niddk.nih.gov/statistics/uda/

A report incorporating current and retrospective data on all aspects of the epidemiology, practice patterns, costs, and impact of urologic diseases in the United States and is intended for use by public officials, nongovernment organizations, the media, academic researchers, health professionals, and the public. The UDA compendium consists of data tables annotated in chapters that amplify the data analyses. The objectives of the UDA project include: secondary data analyses of: changes in the overall healthcare burden for individual urologic diseases, in physician practice patterns for each urologic disease, and in demographics of persons with urologic disease, the impact of specific urologic diseases, especially diseases of the prostate, on the minority populations of the U.S., and documentation of new and evolving therapies for urologic disease and their cost.

Proper citation: Urologic Diseases in America (RRID:SCR_006644) Copy   

•   Source: SciCrunch Registry

http://www.nlm.nih.gov/

NLM collects, organizes, and makes available biomedical science information to scientists, health professionals, and the public. The Library's Web-based databases, including PubMed/Medline and MedlinePlus, are used extensively around the world. NLM conducts and supports research in biomedical communications; creates information resources for molecular biology, biotechnology, toxicology, and environmental health; and provides grant and contract support for training, medical library resources, and biomedical informatics and communications research. Celebrating its 175th anniversary in 2011, the National Library of Medicine (NLM), in Bethesda, Maryland, is a part of the National Institutes of Health, U.S. Department of Health and Human Services (HHS). Since its founding in 1836 as the library of the U.S. Army Surgeon General, NLM has played a pivotal role in translating biomedical research into practice. It is the world's largest biomedical library and the developer of electronic information services that deliver trillions of bytes of data to millions of users every day. Scientists, health professionals, and the public in the United States and around the globe search the Library's online information resources more than 1 billion times each year. The Library is open to all and has many services and resources for scientists, health professionals, historians, and the general public. NLM has over 17 million books, journals, manuscripts, audiovisuals, and other forms of medical information on its shelves, making it the largest health-science library in the world. In today's increasingly digital world, NLM carries out its mission of enabling biomedical research, supporting health care and public health, and promoting healthy behavior by: * Acquiring, organizing, and preserving the world's scholarly biomedical literature; * Providing access to biomedical and health information across the country in partnership with the 5,800-member National Network of Libraries of Medicine (NN/LM); * Serving as a leading global resource for building, curating and providing sophisticated access to molecular biology and genomic information, including those from the Human Genome Project and NIH Common Fund; * Creating high-quality information services relevant to toxicology and environmental health, health services research, and public health; * Conducting research and development on biomedical communications systems, methods, technologies, and networks and information dissemination and utilization among health professionals, patients, and the general public; * Funding advanced biomedical informatics research and serving as the primary supporter of pre- and post-doctoral research training in biomedical informatics at 18 U.S. universities.

Proper citation: National Library of Medicine (RRID:SCR_011446) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/36

Data set and biosepecimens of a multi-center clinical trial to determine if treatment with beta-cell antigens can delay the onset of Type 1 Diabetes Mellitus (Type 1 DM) in non-diabetic relatives of persons with Type 1 DM. Insulin is a well characterized antigen specifically produced by beta-cells, and it was used for this purpose in the initial DPT-1 studies. The protocol for high risk subjects uses daily subcutaneous insulin injections and an annual course of intravenous insulin treatment, while the protocol for intermediate risk subjects uses daily doses of insulin administered orally. Neither injected nor oral insulin at the doses used were observed to delay or prevent diabetes, although further studies are needed to test whether oral insulin can delay diabetes in people in the intermediate risk group with high titers of insulin autoantibodies.

Proper citation: Diabetes Prevention Type 1 (RRID:SCR_001467) Copy   

•   Source: SciCrunch Registry

https://www.clinicaltrials.gov/study/NCT00360646

Prospective and retrospective registry of well-characterized cases of drug-induced liver disease. The goals of Network include the development of standardized procedures to identify and fully characterize bona fide cases of drug- and complementary and alternative medicines (CAM)-induced liver injury, and to conduct controlled, clinical studies that will include extensive collection of data, serum, DNA, and tissue specimens. Cases of liver injury due to herbal medications are also included. The network will also develop terminology and standardized definitions for DILI, and to develop causality assessment instruments that are sensitive, specific, and reproducible. DILIN is funded by a cooperative agreement and includes five clinical centers and a central data coordinating center. The research goals of DILIN are to: * Create a registry of carefully documented DILI cases * Identify clinical, immunological, and environmental risk factors for drug- and CAM-mediated hepatotoxicity * Create a bank of biological specimens consisting of DNA, plasma, and immortalized lymphocytes to facilitate detailed genetic analyses * Characterize the natural history of drug- and CAM-induced DILI for at least six months following enrollment * Develop the capability to recontact these individuals over an extended period of time so that additional studies exploring DILI mechanisms can be performed Two studies are being initiated by the network. In the Retrospective Study, the implicated drugs are restricted to isoniazid, phenytoin, combination clavulanic acid/amoxicillin, and valproic acid (Depakote), Nitrofurantoin, Trimethoprim-sulfamethoxazole, Minocycline, and Quinolone antibiotics. These drugs were chosen because they are frequently administered to patients not receiving other hepatotoxic drugs, making it easier to establish causality. Patients must be alive, and the date of onset of the DILI episode must be on or after January 1, 1994. In the Prospective Study, all incident cases of drug- and CAM-induced liver injury are being considered. Initial presentation to a healthcare professional must be within the previous six months. A detailed medication history of the implicated DILI drug together with all prescription, OTC, and herbal medications is being recorded. Liver and serological tests are being performed to characterize the injury and to exclude competing causes of liver injury. A blood sample is also being drawn for plasma storage and DNA isolation. These cases will be followed longitudinally to characterize the long-term effects of the DILI episode. For both studies, documented, clinically significant DILI must be recorded in the patient's medical charts so that a causal determination can be made. Patients will be excluded if they are unwilling or unable to provide a blood sample or participate in the genetics component. Children under two years of age at the time of enrollment are excluded due to blood-volume requirements. If you have patients who are eligible to participate in either study, please contact one the DILIN clinical sites. As a general policy, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigator-initiated research project applications for ancillary studies to ongoing, large-scale clinical trials, epidemiological studies, and disease databases supported by the Institute. These studies are focused on a wide range of diseases and conditions including diabetes, obesity, acute and chronic liver disease, chronic kidney disease, and benign prostatic hyperplasia, among others.

Proper citation: Drug-Induced Liver Injury Network (RRID:SCR_001524) Copy   

•   Source: SciCrunch Registry